Company Profile
Biogen Stock Price, News & Analysis
- Ticker:
- BIIB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
200.14 USD (-1.01%)
Close
Last updated: July 27, 2026
27.9B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, BIIB closed down 1.01% at $200.14. No new same-company headline was identified in the current news window.
Company overview
Business overview
Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.
Geographic Base and Sector Classification
Biogen is headquartered in the United States and listed on NASDAQ. It sits in large-cap biotechnology with a neuroscience identity.
Business Model Characteristics
The company generates value through product sales, lifecycle management, and ongoing R&D in difficult CNS and rare-disease areas. Investors watch launch execution, pipeline progress, and franchise durability.
Position Within the Biotechnology Landscape
Biogen occupies one of the most important large-cap neuroscience positions in biotech. It is far less binary than a small-cap name, but major pipeline and label events still matter a lot.
Future catalysts
Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise. The market will watch whether the commercial base keeps broadening.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
CAPR · Source: Capricor Therapeutics
- 04
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 05
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
KRYS · Source: Krystal Biotech
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Biogen (BIIB)?
Biogen (BIIB) most recently closed at 200.14 USD, a -1.01% move versus the previous session.
What is the market cap of Biogen (BIIB)?
Biogen currently has a market capitalization of 27.9B USD on BioPharmSignal.
What does Biogen do?
Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.
On which exchange is BIIB stock listed?
Biogen (BIIB) is associated with NASDAQ, United States, Biopharma.
What is lecanemab?
Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise.
Which conditions is Biogen targeting with lecanemab?
Biogen is associated with rare disease, neuroscience based on its company overview and current catalyst commentary.
How does Biogen describe recent progress with lecanemab?
Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise.
What is Biogen?
Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders.